Yang, Huiqin; Craig, Dawn; Epstein, David; Bojke, Laura; … - In: PharmacoEconomics 30 (2012) 4, pp. 257-270
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of golimumab (Schering … controlled trial (GO-REVEAL) that compared golimumab with placebo for the treatment of active and progressive patients who were … symptomatic despite the use of previous DMARDs or NSAIDs. The 14-week data showed that, compared with placebo, golimumab 50 mg …